Divi's Lab Peer Comparison
NSE: DIVISLAB | BSE: 532488
₹9,357.00
₹-4.00
(-0.04%)
As on 09-Oct-2026 14:54IST
Market cap
₹2,48,322 Cr
Revenue (TTM)
₹11,230 Cr
P/E Ratio
84.9
P/B Ratio
14.1
Div. Yield
0.3 %
Edit
| Divi's Lab | Emcure Pharmaceuticals | Neuland Lab | Alivus Life Sciences | Concord Biotech | |
|---|---|---|---|---|---|
Market cap (₹ Cr) |
2,48,322 | 34,906 | 26,964 | 16,244 | 13,951 |
Revenue (₹ Cr) |
11,230 | 9,683 | 2,372 | 2,590 | 1,108 |
Net Profit (₹ Cr) |
2,925.00 | 1,018.97 | 497.77 | 603.02 | 270.18 |
Net Margin (%) |
25.04 | 10.47 | 20.72 | 22.63 | 23.29 |
RoE (%) |
18.53 | 21.30 | 28.49 | 19.61 | 14.45 |
Price to Earnings |
84.90 | 34.51 | 54.17 | 26.94 | 50.66 |
Price-To-Book |
14.06 | 6.67 | 13.34 | 4.66 | 6.73 |
Income Statement (₹ Cr)
| Divi's Lab | Emcure Pharmaceuticals | Neuland Lab | Alivus Life Sciences | Concord Biotech | |
|---|---|---|---|---|---|
|
Operating Revenue
|
11,230.00 | 9,683.45 | 2,371.81 | 2,590.40 | 1,108.39 |
|
Total Income
|
11,682.00 | 9,730.84 | 2,402.61 | 2,664.23 | 1,159.90 |
|
Total Expenditure
|
7,263.00 | 7,739.53 | 1,608.91 | 1,753.71 | 720.01 |
|
EBITDA
|
3,967.00 | 1,943.92 | 762.90 | 836.69 | 388.38 |
|
Depreciation
|
484.00 | 425.10 | 98.11 | 78.88 | 74.78 |
|
EBIT
|
3,483.00 | 1,518.82 | 664.79 | 757.81 | 313.60 |
|
Interest
|
26.00 | 148.45 | 26.33 | 5.43 | 0.26 |
|
Other Income
|
452.00 | 47.39 | 30.80 | 73.83 | 51.50 |
|
Exceptional Items
|
-74.00 | -27.85 | 0.00 | -25.66 | -3.28 |
|
Profit before Tax
|
3,835.00 | 1,389.91 | 669.26 | 800.55 | 361.56 |
|
Provision for Tax
|
910.00 | 370.94 | 171.48 | 197.53 | 91.39 |
|
Profit after Tax
|
2,925.00 | 1,018.97 | 497.77 | 603.02 | 270.18 |
Liabilities (₹ Cr)
| Divi's Lab | Emcure Pharmaceuticals | Neuland Lab | Alivus Life Sciences | Concord Biotech | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
16,761.00 | 4,950.03 | 1,874.47 | 3,332.13 | 2,017.06 |
|
Minority Interest
|
0.00 | -7.58 | 0.00 | 0.00 | 2.51 |
|
Non-Current Liabilities
|
1,229.00 | 723.57 | 345.47 | 142.73 | 50.51 |
|
Current Liabilities
|
2,043.00 | 3,912.24 | 710.20 | 508.04 | 169.08 |
|
Total Liabilities
|
20,878.00 | 9,514.48 | 2,930.14 | 4,157.10 | 2,231.79 |
Assets (₹ Cr)
| Divi's Lab | Emcure Pharmaceuticals | Neuland Lab | Alivus Life Sciences | Concord Biotech | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
8,717.00 | 3,392.16 | 1,290.62 | 1,321.38 | 957.22 |
|
Current Assets
|
11,096.00 | 5,612.10 | 1,483.13 | 2,649.36 | 1,250.11 |
|
Total Assets
|
20,878.00 | 9,514.48 | 2,930.14 | 4,157.10 | 2,231.79 |
|
Total Debt*
|
0.00 | 1,204.08 | 196.61 | 0.00 | 0.00 |
|
Net Current Assets
|
9,053.00 | 1,699.86 | 772.93 | 2,141.33 | 1,081.04 |
|
Contingent Liabilities
|
8.00 | 258.92 | 13.18 | 4.82 | 3.76 |
Cashflow (₹ Cr)
| Divi's Lab | Emcure Pharmaceuticals | Neuland Lab | Alivus Life Sciences | Concord Biotech | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
2,738.00 | 943.55 | 346.68 | 565.41 | 266.88 |
|
Cash Flow from Investing Activities
|
-2,219.00 | -1,193.06 | -423.73 | -570.15 | -142.72 |
|
Cash from Financing Activities
|
-804.00 | 343.43 | 20.98 | -64.34 | -112.88 |
|
Net Cash Inflow / Outflow
|
-285.00 | 93.92 | -56.08 | -69.08 | 11.28 |
Ratios
Profitability Ratios
| Divi's Lab | Emcure Pharmaceuticals | Neuland Lab | Alivus Life Sciences | Concord Biotech | |
|---|---|---|---|---|---|
|
ROCE (%)
|
21.51 | 25.25 | 27.50 | 24.61 | 18.04 |
|
ROE (%)
|
18.53 | 21.30 | 28.49 | 19.61 | 14.45 |
|
ROA (%)
|
15.83 | 11.42 | 19.48 | 16.31 | 12.66 |
|
EBIT Margin (%)
|
31.02 | 15.68 | 28.03 | 29.25 | 28.29 |
|
Net Margin (%)
|
25.04 | 10.47 | 20.72 | 22.63 | 23.29 |
|
Cash Profit Margin (%)
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Growth Ratios
| Divi's Lab | Emcure Pharmaceuticals | Neuland Lab | Alivus Life Sciences | Concord Biotech | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
16.35 | 18.36 | 78.33 | 7.93 | -6.72 |
|
EBIT Growth (%)
|
31.09 | 30.43 | 303.07 | 19.88 | -26.64 |
|
Net Profit Growth (%)
|
26.84 | 32.39 | 182.61 | 21.66 | -24.38 |
|
EPS Growth (%)
|
29.24 | 36.68 | 277.72 | 25.42 | -21.99 |
|
Book Value Growth (%)
|
11.97 | 11.36 | 22.95 | 18.43 | 11.27 |
Valuation Ratios
| Divi's Lab | Emcure Pharmaceuticals | Neuland Lab | Alivus Life Sciences | Concord Biotech | |
|---|---|---|---|---|---|
|
Price / Earnings
|
83.63 | 34.01 | 54.16 | 26.37 | 50.08 |
|
Price / Book Value
|
14.11 | 6.71 | 13.34 | 4.71 | 6.71 |
|
Dividend Yield (%)
|
0.32 | 0.19 | 0.16 | 0.37 | 0.57 |
|
EV/EBITDA
|
61.97 | 18.61 | 35.13 | 18.69 | 34.75 |
|
Market Cap (₹ Cr)
|
1,57,583.71 | 30,257.56 | 15,412.11 | 11,956.86 | 10,627.92 |
Solvency Ratios
| Divi's Lab | Emcure Pharmaceuticals | Neuland Lab | Alivus Life Sciences | Concord Biotech | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.00 | 0.05 | 0.09 | 0.00 | 0.00 |
|
Short term debt to equity ratio
|
-- | 0.16 | -- | -- | -- |
|
Current Ratio
|
5.43 | 1.43 | 2.09 | 5.21 | 7.39 |
|
Quick Ratio
|
3.50 | 0.82 | 1.37 | 3.85 | 5.46 |
|
Interest Coverage
|
148.50 | 10.36 | 26.41 | 148.49 | 1,386.30 |
Operating Efficiency Ratios
| Divi's Lab | Emcure Pharmaceuticals | Neuland Lab | Alivus Life Sciences | Concord Biotech | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
26.57 | 26.46 | 22.82 | 41.42 | 41.52 |
|
Asset Turnover
|
0.61 | 1.09 | 0.93 | 0.70 | 0.52 |
|
Receivable days
|
99.21 | 88.68 | 77.32 | 144.58 | 169.86 |
|
Inventory Days
|
124.81 | 84.11 | 80.83 | 96.67 | 97.92 |
|
Payable days
|
94.57 | 176.65 | 125.94 | 135.45 | 159.68 |
|
Cash Conversion Cycle
|
129.45 | -3.86 | 32.22 | 105.80 | 108.11 |
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
loading...
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
